[
    [
        {
            "time": "2018-01-03",
            "original_text": "FDA approves J&J prostate cancer treatment",
            "features": {
                "keywords": [
                    "FDA",
                    "approves",
                    "J&J",
                    "prostate",
                    "cancer",
                    "treatment"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "ONGOING INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Johnson & Johnson",
            "features": {
                "keywords": [
                    "ONGOING",
                    "INVESTIGATION",
                    "Schall",
                    "Law",
                    "Firm",
                    "Investigating",
                    "Claims",
                    "Johnson",
                    "&",
                    "Johnson"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "Scott+Scott, Attorneys at Law, LLP Alerts Investors to the Filing of a Securities Class Action Against Johnson & Johnson (JNJ)",
            "features": {
                "keywords": [
                    "Scott+Scott",
                    "Attorneys",
                    "Law",
                    "LLP",
                    "Alerts",
                    "Investors",
                    "Securities",
                    "Class",
                    "Action",
                    "Against",
                    "Johnson",
                    "&",
                    "Johnson",
                    "(JNJ)"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 1,
                "Importance": 7,
                "Impact": 4,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "JNJ SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Johnson & Johnson",
            "features": {
                "keywords": [
                    "JNJ",
                    "SHAREHOLDER",
                    "ALERT",
                    "Law",
                    "Offices",
                    "Vincent",
                    "Wong",
                    "Notifies",
                    "Investors",
                    "Investigation",
                    "Securities",
                    "Fraud",
                    "Violations",
                    "Board",
                    "Directors",
                    "Johnson",
                    "&",
                    "Johnson"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 7,
                "Impact": 4,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "What To Expect From Roche In 2018",
            "features": {
                "keywords": [
                    "Expect",
                    "Roche",
                    "2018"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "Cory Booker joins Kirsten Gillibrand and other Senate Democrats in rejecting corporate PAC donations",
            "features": {
                "keywords": [
                    "Cory",
                    "Booker",
                    "joins",
                    "Kirsten",
                    "Gillibrand",
                    "Senate",
                    "Democrats",
                    "rejecting",
                    "corporate",
                    "PAC",
                    "donations"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "politics"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "false"
            },
            "scores": {
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 2,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 1,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "Inside Pfizer’s Inflammation and Immunology Portfolio Performances in 2017",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Inflammation",
                    "Immunology",
                    "Portfolio",
                    "Performances",
                    "2017"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-10",
            "original_text": "Bristol-Myers Squibb’s Valuation after Its 4Q17 Earnings",
            "features": {
                "keywords": [
                    "Bristol-Myers",
                    "Squibb",
                    "Valuation",
                    "4Q17",
                    "Earnings"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-11",
            "original_text": "The Decline In Johnson & Johnson Could Be Close to Being Over",
            "features": {
                "keywords": [
                    "Decline",
                    "Johnson",
                    "&",
                    "Johnson",
                    "Close",
                    "Over"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-12",
            "original_text": "Behind Pfizer’s Internal Medicines in 2017",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Internal",
                    "Medicines",
                    "2017"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-13",
            "original_text": "Bristol-Myers Squibb’s Orencia and Other Brands in 4Q17",
            "features": {
                "keywords": [
                    "Bristol-Myers",
                    "Squibb",
                    "Orencia",
                    "Brands",
                    "4Q17"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        }
    ]
]